Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May-Jun;39(3):e70117.
doi: 10.1111/jvim.70117.

Long-Term Firocoxib Use in Horses

Iuri Buzelato Carli  1 , Langdon Fielding  1
Affiliations

Long-Term Firocoxib Use in Horses

Iuri Buzelato Carli et al. J Vet Intern Med. 2025 May-Jun.

Abstract

Background: Many horses receive firocoxib over multiple years, and studies evaluating hematologic and biochemical values in these animals are lacking.

Objective: To describe the hematologic and biochemical values of horses receiving long-term firocoxib.

Animals: A total of 79 horses receiving long-term firocoxib and 153 horses not receiving long-term firocoxib and not presenting for a specific medical problem.

Methods: Retrospective study comparing horses receiving firocoxib (F group) and no firocoxib (NF group). Signalment, hematologic, and biochemical values were compared between the two groups. Simple linear regression was used to evaluate the relationship between the duration of firocoxib administration and specific laboratory variables.

Results: Horses receiving long-term firocoxib (F) were 19 (5-33) years as compared to 15 (1-33) years for the NF group (p < 0.0001). The most common reason for receiving firocoxib was osteoarthritis in 44/79 (56%) of the animals in the F group. Horses in the F group had a total protein concentration of 6.6 (5.8-8.0) g/dL as compared to 6.5 (5.1-8) g/dL in the NF group (p = 0.03). The sodium concentration for F horses was 139 (133-143) mmol/L as compared to 138 (129-145) mmol/L for NF horses (p = 0.01). Total white blood cell count was 6.11 (2.82-14.36) 103 cells/uL in the F group as compared to 6.46 (3.04-14.71) 103 cells/uL in the NF group (p = 0.03). None of the laboratory variables were associated with the duration of firocoxib administration.

Conclusions and clinical importance: Many horses receive firocoxib for multiple years, and equine practitioners should be aware that expected changes in laboratory values are minimal.

Keywords: NSAID; creatinine; lameness; renal; surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Bergh M. S. and Budsberg S. C., “The Coxib NSAIDs: Potential Clinical and Pharmacologic Importance in Veterinary Medicine,” Journal of Veterinary Internal Medicine 19 (2005): 633–643. - PubMed
    1. Doucet M. Y., Bertone A. L., Hendrickson D., et al., “Comparison of Efficacy and Safety of Paste Formulations of Firocoxib and Phenylbutazone in Horses With Naturally Occurring Osteoarthritis,” Journal of the American Veterinary Medical Association 232, no. 1 (2008): 91–97. - PubMed
    1. Kvaternick V., Pollmeier M., Fischer J., et al., “Pharmacokinetics and Metabolism of Orally Administered Firocoxib, a Novel Second Generation Coxib, in Horses,” Journal of Veterinary Pharmacology and Therapeutics 30, no. 3 (2007): 208–217. - PubMed
    1. Autefage A., Palissier F. M., Asimus E., and Pepin‐Richard C., “Long‐Term Efficacy and Safety of Firocoxib in the Treatment of Dogs With Osteoarthritis,” Veterinary Record 168, no. 23 (2011): 617. - PubMed
    1. Rangel‐Nava A., Ramírez‐Uribe J. M., Recillas‐Morales S., Ibancovichi‐Camarillo J. A., Venebra‐Muñoz A., and Sánchez‐Aparicio P., “Pharmacological Regulation in the USA and Pharmacokinetics Parameters of Firocoxib, a Highly Selective Cox‐2, by Pain Management in Horses,” Journal of Equine Veterinary Science 77 (2019): 36–42. - PubMed

MeSH terms

LinkOut - more resources